Caldas, Stella
Pagan, Angel D.
Correa da Rosa, Joel
Kim, Brian S.
Ungar, Benjamin
Article History
Received: 15 June 2023
Revised: 15 June 2023
Accepted: 27 July 2023
First Online: 7 August 2023
Declarations
:
: BU is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Incyte, Rapt Therapeutics, and Pfizer. He is also a consultant for Arcutis Biotherapeutics, Castle Biosciences, Fresenius Kabi, Pfizer, and Sanofi. BSK is an employee of Mount Sinai. He also has received personal fees from AbbVie, Argenx, Abrax, Japan, Almirall, S.A., Amagma, Amgen, Bristol-Myers Squibb, Cara Therapeutics, Eli Lilly and Company, Evommune, Escient Pharmaceuticals, Galderma S.A., GlaxoSmithKline, Genzyme, Granular Therapeutics, Guidepoint Global, Incyte Corporation, Janssen Pharmaceuticals, Inc., LEO Pharma, Pfizer Inc., Novartis, Recens Medical, Regeneron, and Trevi Therapeutics. JCDR is an employee of Mount Sinai. The rest of the authors declare no relevant conflicts of interest.